2018;197:27 34. S4.1.1-42. Fanola CL, Giugliano RP, Ruff CT, et al. A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. Eur Heart J. 2017;38:888 96. S4.1.1-43. Philippart R, Brunet-Bernard A, Clementy N, et al. CHA2DS2-VASc score for predicting stroke and thromboembolism in patients with AF and biological valve prosthesis. J Am Coll Cardiol. 2016;67:343 4. S4.1.1-44. Carnicelli AP, De Caterina R, Halperin JL, et al. Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves. Circulation. 2017;135:1273 5. S4.1.1-45. Pokorney SD, Rao MP, Wojdyla DM, et al. Apixaban use in patients with atrial fibrillation with bioprosthetic valves: insights from ARISTOTLE. [abstract 17277]. Circulation 2015;132 suppl 3:A17277. S4.1.1-46. Puskas J, Gerdisch M, Nichols D, et al. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg. 2014;147:1202 10; dis- cussion 1210 1. S4.1.1-47. ELIQUIS (apixaban) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2012. S4.1.1-48. Savaysa [package insert] 2015. Daiichi Sankyo, Inc; Parsippany, NJ. S4.1.1-49. Nielsen PB, Skj th F, Overvad TF, et al. Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA2DS2-VA score rather than CHA2DS2-VASc? Circulation. 2018;137:832 40. S4.1.1-50. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of throm- bosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e531S 75. S4.1.1-51. US Renal Data System. 2016 USRDS annual data report: epidemiol- ogy of kidney disease in the United States. Bethesda, MD. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2016. S4.1.1-52. 